[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The First Affiliated Hospital of Nanchang University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":317},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,43,75,105,128,155,172,188,211,226,241,257,272,291],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100595208","comparison-of-short--and-long-term-outcomes-between-robotic-and-laparoscopic-hemicolectomy-of-right-colon-cancer--a-multicenter-propensity-score-matching-analysis-100595208",false,"NCT07029464","Comparison of Short- and Long-term Outcomes Between Robotic and Laparoscopic Hemicolectomy of Right Colon Cancer : A Multicenter Propensity Score Matching Analysis","Inclusion Criteria:\n\n* 1.Underwent radical right hemicolectomy by Da Vinci robotic or laparoscopic surgery 2.Postoperative pathology confirmed right colon adenocarcinoma (pT2-T4aNxM0; including cecal adenocarcinoma, ascending colon adenocarcinoma, hepatic flexure colon adenocarcinoma, and proximal transverse colon adenocarcinoma) 3.Complete clinical data and pathological results available\n\nExclusion Criteria:\n\n* 1.Received neoadjuvant therapy prior to surgery 2.History of other malignancies in the past 5 years (except cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin) 3.Distant metastases (e.g., liver, lung) or extensive abdominal\u002Fpelvic metastases confirmed by contrast-enhanced CT, PET-CT, or intraoperative exploration 4.Comorbid neurological\u002Fpsychiatric disorders impairing ability to express informed consent 5.Poor systemic condition with contraindications to general anesthesia 6.Severe obesity (BMI \\>35 kg\u002Fm²) 7.Severe widespread abdominal adhesions precluding safe pneumoperitoneum establishment 8.Emergency surgery due to tumor perforation or obstruction 9.Refusal to provide informed consent","ALL","18 Years","80 Years",{"count":19,"type":20},4000,"ESTIMATED","OBSERVATIONAL","This is a retrospective, multicenter cohort study to compare short- and long-term outcomes between robotic and laparoscopic hemicolectomy of right colon cancer.",[24,25,26,27],"Robotic Surgical Procedures","Right Colon Tumors","Cancer","Laparoscopic Abdominal Surgery",[29,30],"right colon cancer","robotic surgery","NOT_YET_RECRUITING","2025-06-17",{"date":34,"type":35},"2025-06-19","ACTUAL",{"date":37,"type":20},"2025-06",{"date":39,"type":20},"2027-05",{"name":41,"class":42},"The First Affiliated Hospital of Nanchang University","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100592868","early-phase-1-a-study-to-evaluate-cg-105-12-in-patients-with-relapsedrefractory-multiple-myeloma-100592868","NCT06999031","A Study to Evaluate CG-105-12 in Patients With Relapsed\u002FRefractory Multiple Myeloma","An Exploratory Clinical Study on the Safety and Efficacy of Autologous T Cell Injection Targeting BCMA Chimeric Antigen Receptor (CG-105-12) in the Treatment of Patients With Relapsed \u002F Refractory Multiple Myeloma","Inclusion Criteria:\n\n* 1.Aged 18-75 years (inclusive of 18 and 75 years old), gender not limited;\n* 2.Subject has received at least 3 lines of therapy, including at least proteasome inhibitors (PIs) and immunomodulatory therapy (IMiD); disease relapse, progression, or refractory according to the International Myeloma Working Group (IMWG) Consensus (2016) criteria for multiple myeloma;\n* 3.Subjects whose tumor specimens were positive for BCMA expression on the membrane surface of plasma cells by immunohistochemistry (IHC) or flow cytometry and had not received prior BCMA CAR-T therapy;\n* 4.One of the following is met (all data below are compared to the obtained minimum values):\n* \\- a. Serum M-protein increased by more than 25% (absolute increase greater than 5 g\u002FL) or M-protein increased by more than 10 g\u002FL (if baseline serum M-protein is greater than 50 g\u002FL);\n* \\- b. Uroprotein increased by more than 25% (absolute increase greater than 200 mg\u002F24h);\n* \\- c. The difference between affected and unaffected serum FLC increased by more than 25% and the absolute value increased by more than 100 mg\u002FL;\n* \\- d.The proportion of bone marrow plasma cells increased by more than 25% and the absolute value increased by more than 10%;\n* \\- e. The sum of the original maximum vertical diameter products of more than one measurable lesion increased by at least 50% from the lowest point; or the long axis of the original lesion of at least 1 cm increased by at least 50%;\n* \\- f. An increase in circulating plasma cells of at least 50% (used when only circulating plasma cells are measurable lesions, with an absolute value of at least 200 cells per microlitre);\n* 5.ECOG performance status score of 0-2；\n* 6.Expected survival ≥12 weeks；\n* 7.Subjects must have adequate organ function and meet all of the following laboratory test results prior to enrollment:\n* \\- a.Complete blood count: Neutrophil count (ANC) 1E9\u002FL; Lymphocyte count (ALC) 0.5E9\u002FL; Platelet count \\>50E9\u002FL; Haemoglobin \\>60g\u002FL or Haematocrit \\>0.24；\n* \\- b.Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 2.5 times the upper limit of normal (ULN); serum total bilirubin less than 1.5 times the ULN;\n* \\- c.Renal function: The creatinine clearance rate calculated according to the Cockcroft-Gault formula is GFR 40ml\u002Fmin (except for those whose renal function is abnormal due to progression of the primary disease as judged by the investigator);\n* \\- d.Coagulation function: fibrinogen ≥ 1.0 g\u002FL; activated partial thromboplastin time ≤1.5×ULN, prothrombin time (PT) ≤ 1.5×ULN;\n* \\- e.Blood oxygen saturation \\> 91%;\n* \\- f.Left ventricular ejection fraction (LVEF) ≥ 50%;\n* 8.Subjects and their spouses agreed to use effective instrumental or medical contraception (except for safe contraception) from the time of signing the informed consent form until one year after CAR-T cell reinfusion;\n* 9.Participants must personally sign a written informed consent form approved by the Ethics Committee prior to the start of any screening procedure.\n\nExclusion Criteria:\n\n* 1.Hepatitis B surface antigen (HBsAg) positive, or Hepatitis B core antibody (HBcAb) positive with detectable Hepatitis B Virus (HBV) DNA in peripheral blood; Hepatitis C Virus (HCV) antibody positive with peripheral blood positive for Hepatitis C Virus (HCV) RNA; Human Immunodeficiency Virus (HIV) antibody positive; and Syphilis test positive.\n* 2.Prior antitumor therapy as follows:\n* \\- a.Treatment of multiple myeloma with monoclonal antibodies, CNS radiotherapy within 8 weeks prior to single nucleated cell collection;\n* \\- b.or cytotoxic chemotherapy, immunomodulator therapy, or proteasome inhibitor therapy within 14 days prior to single nucleated cell collection;\n* \\- c.or have received granulocyte-macrophage colony-stimulating factor (GM-CSF), long-acting granulocyte colony-stimulating factor (G-CSF) within 14 days prior to the single nucleated cell collection;\n* 3.Has used therapeutic doses of corticosteroids (defined as prednisone or equivalent \\>20 mg\u002Fday) within 7 days prior to screening, but physiologic replacement, topical and inhaled steroids are permitted;\n* 4.have received treatment containing bendamustine or fludarabine within 12 weeks prior to screening;\n* 5.Plasma cell leukemia, patients suspected or suspected of having plasma cell tumor central nervous system invasion during screening;\n* 6.patients with previous allogeneic hematopoietic stem cell transplantation;\n* 7.malignancies other than multiple myeloma within 5 years prior to screening, excluding adequately treated carcinoma in situ of the cervix, basal cell or squamous epithelial cell skin cancers, localized prostate cancer after radical surgery, and ductal carcinoma in situ of the breast after radical surgery;\n* 8.subjects with a history of solid organ transplantation;\n* 9.Subjects who have undergone major surgery ( 3 level) within 2 weeks prior to the collection of individual nuclear cells, or who plan to have surgery within 2 weeks after the study treatment (subjects who plan to have local anesthesia surgery can participate in this study);\n* 10.have received a live attenuated vaccine within ≤ 4 weeks prior to administration of the pretreatment regimen;\n* 11.Presence of severe underlying diseases, such as:\n* \\- a.Patients with autoimmune diseases (systemic lupus erythem- atosus, multiple sclerosis, rheumatoid arthritis, etc.) who need long-term use of immunosuppressants (methotrexate, cycl - ophosphamide, etc.), biological agents (infliximab, tozumab, etc.), glucocorticoids (prednisone, dexamethasone, etc.);\n* \\- b.Uncontrolled active infection within 7 days prior to collection of a single nuclear cell, and evidence of severe active viral, bacterial infection or uncontrolled systemic fungal infection;\n* \\- c.Diabetes that cannot be controlled by combination therapy;\n* \\- d.Severe cardiac disease: including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (NYHA \\[NYHA\\] class III or higher), and severe arrhythmia;\n* \\- e.Patients with hypertension that cannot be controlled by drug therapy, that is, those with hypertension who cannot be reduced to the following range after combined treatment with 2 drugs (systolic blood pressure \\\u003C160 mmHg, diastolic blood pressure \\\u003C100 mmHg);\n* \\- f.Comorbid psychiatric or psychotic disorders or central nervous system disorders;\n* 12.receiving other interventional clinical trial medications within 1 month prior to signing the Informed Consent Form (ICF);\n* 13.Pregnant or breastfeeding women, women\u002Fmen of chil - dbearing age who have a plan to become pregnant during the trial period and within 6 months after the end of the trial;\n* 14.Patients with a history of severe allergic reaction, or allergic reaction to any drug and related excipient specified in the protocol and judged by the investigator not suitable for enrollment;\n* 15.Other conditions that the investigator considers unsuitable for enrollment.","75 Years",{"count":52,"type":20},12,"INTERVENTIONAL",[55],"EARLY_PHASE1","This study is a single-centre, single-arm, open-label, dose-escalation exploratory study with single-dose administration. Its objective is to evaluate the safety, tolerability, dose, anti-tumor efficacy, and pharmacokinetic characteristics of CG-105-12 in the participants with BCMA-positive relapsed\u002Frefractory multiple myeloma who previously received adequate but uneffective standard treatments.",[58,59],"Relapsed\u002FRefractory","Multiple Myeloma",[61,62,63,64],"multiple myeloma","relapsed\u002Frefractory","chimeric antigen receptor T Cell","BCMA","RECRUITING","2025-05-22",{"date":68,"type":35},"2025-05-31",{"date":70,"type":35},"2024-09-05",{"date":72,"type":20},"2027-09-30",{"name":41,"class":42},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":53,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":74},"100496852","using-neoantigen-peptide-vaccineneoantigen-based-dc-to-treat-advanced-malignant-solid-tumors-100496852","NCT05749627","Using Neoantigen Peptide Vaccine\u002Fneoantigen-based DC to Treat Advanced Malignant Solid Tumors","A Clinical Study of Personalized Tumor Neoantigen Peptide Vaccine\u002Fneoantigen-based Dendritic Cells in the Treatment of Advanced Malignant Solid Tumors","Inclusion Criteria:\n\n* With inoperable advanced malignant solid tumors, including melanoma, gastrointestinal tumor, breast cancer, pancreatic cancer, cervical cancer, lung cancer, etc.\n* Failed in standard treatment or voluntarily give up other treatment, and been longer than 2 weeks from the end of the last anti-tumor treatment\n* Had disease progression prior to treatment\n* Expected survival ≥ 3 months\n* ECOG performance status of 0, 1, or 2\n* With a negative pregnancy test for females of childbearing age\n* Able to take effective contraceptive measures and ensure that there is no birth plan within half a year of the study\n* Not positive for HIV, HBV, HCV, or TP\n* ALT\u002FAST ≤ 2.5 times the upper limit of normal\n* ALP ≤ 2.5 times the upper limit of normal\n* Serum creatinine ≤1.6 mg\u002FdL\n* Total bilirubin ≤ 1.5 mg\u002FdL\n* In the absence of granulocyte colony-stimulating factor support, proportion of lymphocytes \\> 20%, absolute neutrophil count ≥ 1x10\\^9\u002FL, white blood cell count ≥ 3x10\\^9\u002FL, platelet count ≥ 100×10\\^9\u002FL, hemoglobin \\> 8.0 g\u002FdL, CD4+ cell count \\> 200\u002FμL\n* With normal coagulation test and ECG\n* Able to understand and willing to sign a written informed consent form\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patients with brain metastases\n* Had immunosuppressant therapy within 1 month or received other immunotherapy within 3 months\n* Participated in other clinical study within 30 days\n* With severe allergies or histories of severe allergy\n* With splenectomy\n* With primary or secondary immunodeficiency diseases or autoimmune diseases (including systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulitis, psoriasis, uncontrolled asthma, etc.)\n* Had oral, intramuscular, or intravenous corticosteroids within 1 month. However, inhaled corticosteroids are allowed to treat respiratory insufficiency (such as chronic obstructive pulmonary disease), as well as topical steroids\n* With uncontrollable epilepsy, central nervous system disorder, or neurological disease with loss of cognitive ability\n* With a history of chronic alcohol or drug abuse within 6 months\n* With unstable systemic diseases (including active infection, liver cirrhosis, chronic renal failure, severe chronic pulmonary disease, unstable hypertension, unstable angina, congestive heart failure, myocardial infarction within 1 year, etc.)\n* With a history of other malignant tumors in the past 5 years (excluding those who have been clinically cured, and squamous cell carcinoma or skin basal cell carcinoma)\n* Those the researcher believed inappropriate to participate in this study","70 Years",{"count":84,"type":20},20,[86],"NA","In this study, the investigators provide a personalized tumor neoantigen peptide vaccine\u002Fneoantigen-based DC treatment to patients with advanced malignant solid tumors. The investigators observe the post-treatment tumor burden status, the immune response induced by immune preparations, and the prolongation of patient survival time, aiming to evaluate the effectiveness and safety of the neoantigen-based DC treatment.",[89],"Advanced Malignant Solid Tumors",[91,92,93,89,94,95,96],"Neoantigen Peptide Vaccine","Neoantigen-based Dendritic Cells","Therapeutic immune preparation","Progression-free Survival","Overall Survival","Overall Response Rate","2025-02-25",{"date":99,"type":35},"2025-02-27",{"date":101,"type":35},"2023-04-01",{"date":103,"type":20},"2025-12-31",{"name":41,"class":42},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":111,"targetDuration":4,"studyType":53,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":74},"100565233","therapeutic-effect-of-bifidobacterium-longum-in-patients-with-acute-pancreatitis-a-randomized-double-blind-placebo-controlled-trial-100565233","NCT06639516","Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Age 18-75 year;\n2. The diagnosis of acute pancreatitis according to the revised Atlanta classification;\n3. The onset time of acute pancreatitis is within 48 hours;\n4. APACHE II score of ≥8, or C-reactive protein \\> 150 mg\u002FL, or SIRS score of ≥3;\n5. Signed the informed consent.\n\nExclusion Criteria:\n\n1. Within 48 hours of onset, there is multi-organ failure;\n2. Use of probiotics within the last month;\n3. Pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP);\n4. Intra-operative diagnosis;\n5. Infection\u002Fsepsis caused by a second disease;\n6. Malignancy;\n7. Immunocompromised patients;\n8. Pregnancy and\u002For lactation;\n9. Allergy to Bifidobacterium longum.",{"count":112,"type":20},60,[86],"The purpose of this clinical trial is to investigate the impact of Bifidobacterium longum(BL) on the clinical prognosis of patients with acute pancreatitis(AP), to analyze the correlation between BL and intestinal barrier function, as well as the gut microbiota, and to observe adverse reactions and risks in patients with AP after the use of BL.\n\nParticipants will be randomly assigned to two groups: the intervention group and the control group. They will receive:\n\n* Intervention group: Standard clinical treatment + BL capsules (10\\^10 CFU), twice a day, for a total of 14 days;\n* Control group: Standard clinical treatment + placebo capsules, for a total of 14 days.\n\nA total of 60 patients will be included in this study.",[116],"Acute Pancreatitis",[118,119],"acute pancreatitis","Probiotics","2025-02-04",{"date":122,"type":35},"2025-02-06",{"date":124,"type":20},"2025-02-15",{"date":126,"type":20},"2025-12-01",{"name":41,"class":42},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":82,"enrollmentInfo":135,"targetDuration":4,"studyType":53,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100573873","neoantigen-loaded-dc-vaccine-and-conventional-second-line-therapy-for-crc-progressed-after-first-line-treatment-100573873","NCT06751940","Neoantigen-loaded DC Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment","A Multicenter Clinical Study of Personalized Tumor Neoantigen-loaded DC Vaccine Combined with Conventional Second-line Therapy for the Treatment of Colorectal Cancer Progressed After First-line Treatment","Inclusion Criteria:\n\n* Patients with histologically or cytologically confirmed CRC;\n* At least one measurable lesion;\n* Aged 18-70, regardless of gender;\n* Disease progression after standard first-line therapy, and more than 2 weeks since the end of the last antitumor treatment;\n* Expected survival of ≥3 months;\n* ECOG performance status of 0-1;\n* Female patients of childbearing age must have a negative pregnancy test and be able to take effective contraceptive measures with no plans for pregnancy within six months of the study;\n* Able to undergo all screening period laboratory tests as required by the protocol;\n* Normal major organ function, such as heart, liver, and kidney;\n* Hematologic parameters: neutrophil count ≥1.5×10\\^9\u002FL, hemoglobin ≥10g\u002FdL, platelet count ≥100×10\\^9\u002FL, total bilirubin ≤1.5 times the upper limit of normal, AST and ALT ≤2.5 times the upper limit of normal, creatinine and blood urea nitrogen ≤1.5 times the upper limit of normal, activated partial thromboplastin time ≤1.5×ULN, and International Normalized Ratio or prothrombin time ≤1.5×ULN;\n* No active hepatitis, AIDS, syphilis, or other infectious diseases;\n* Rheumatoid panel: C-reactive protein (CRP) ≤10.0mg\u002FL; Anti-streptolysin O (ASO) \\\u003C500U; Erythrocyte sedimentation rate ≤15mm\u002Fh (men) or 20mm\u002Fh (women);\n* Thyroid function tests: 0.27mIU\u002FL ≤ Thyroid-stimulating hormone (TSH) ≤ 4.2mIU\u002FL; 3.1pmol\u002FL ≤ Free triiodothyronine (FT3) ≤ 6.8pmol\u002FL; 12pmol\u002FL ≤ Serum free thyroxine (FT4) ≤ 22pmol\u002FL; 1.3nmol\u002FL ≤ Serum total triiodothyronine (TT3) ≤ 3.1nmol\u002FL; 66nmol\u002FL ≤ Serum total thyroxine (TT4) ≤ 181nmol\u002FL;\n* Adrenocorticotropic hormone (ACTH): 1.1-17.6pmol\u002FL;\n* Ability to understand and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\nDisease-specific exclusion criteria:\n\n* Patients with uncontrollable brain metastases;\n* Subjects expected to require any form of antitumor treatment during the study, including maintenance therapy with other drugs, chemotherapy, and\u002For surgical resection.\n\nExclusion criteria for medical history and comorbidities:\n\n* Subjects who have required systemic treatment with corticosteroids (\\>10 mg\u002Fday of prednisone or equivalent) or other immunosuppressants within 14 days before the first dose. Inhalational or topical corticosteroids are allowed in the absence of active autoimmune diseases;\n* Subjects who have been treated with anticancer immunotherapies or other immunostimulatory anticancer drugs (interferons, interleukins, thymosin, immune cell therapy, etc.) within 3 months before the first dose;\n* Subjects participating in other clinical trials or whose first dose is less than 4 weeks (or 5 half-lives of the study drug) after the end of the previous clinical trial (last dose);\n* Subjects with severe cardiovascular diseases, such as those meeting NYHA Class II or higher criteria, myocardial infarction, or cerebrovascular accidents (cerebral ischemia, symptomatic cerebral embolism, etc.) occurring within 3 months before the first dose, or unstable arrhythmias or unstable angina within 1 month before starting study treatment;\n* Subjects with uncontrolled myocardial ischemia or myocardial infarction, poorly controlled arrhythmias are excluded;\n* Subjects with hypertension that cannot be well controlled by antihypertensive medication (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg) (Note: a stable antihypertensive regimen should be in place within 1 week before the first dose);\n* Subjects who have had significant clinically relevant bleeding symptoms or a clear bleeding tendency within 3 months before the first dose, as well as tumors that have invaded major blood vessels or, in the investigator's judgment, are highly likely to invade major blood vessels and cause major bleeding during treatment. Subjects with obvious hemoptysis, coughing up 2.5 mL or more of blood in the month before the first dose;\n* Subjects who have experienced arterial\u002Fvenous thrombotic events, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral embolism), deep vein thrombosis, and pulmonary embolism, within 3 months before screening;\n* Subjects with active tuberculosis;\n* Subjects who have had a serious infection within 4 weeks before the first dose, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.; Subjects with any active infection;\n* Subjects preparing for or who have previously undergone tissue\u002Forgan transplantation;\n* Subjects with uncontrolled epilepsy, central nervous system disorders, or neurological diseases resulting in cognitive impairment;\n* Subjects with a history of splenectomy.\n\nOther exclusion criteria:\n\n* Pregnant or breastfeeding women;\n* Subjects with a severe history of allergies or atopic constitution;\n* Subjects with a history of chronic alcohol or drug abuse within 6 months before enrollment;\n* Subjects deemed unsuitable for the study by the investigator.",{"count":136,"type":20},10,[86],"In this study, the investigators provide a combined treatment of personalized tumor neoantigen-loaded DC vaccine and conventional second-line therapy to patients with colorectal cancer (CRC) progressed after first-line treatment. The investigators observe the objective response rate (ORR), disease control rate (DCR), adverse event (AE), serious adverse event (SAE), progression-free survival (PFS), and overall survival (OS) , aiming to evaluate the effectiveness and safety of the treatment.",[140],"Colorectal Cancer (CRC)",[142,143,140,144,145],"Tumor Neoantigen","DC Vaccine","Immunotherapy","Second-line Therapy","2024-12-27",{"date":148,"type":35},"2024-12-30",{"date":150,"type":35},"2024-09-01",{"date":152,"type":20},"2027-02-28",{"name":41,"class":42},2,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":82,"enrollmentInfo":162,"targetDuration":4,"studyType":53,"phases":163,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":170,"leadSponsor":171,"locationsCount":154},"100573874","neoantigen-loaded-dc-vaccine-and-conventional-third-line-therapy-for-crc-progressed-after-second-line-treatment-100573874","NCT06751953","Neoantigen-loaded DC Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment","A Multicenter Clinical Study of Personalized Tumor Neoantigen-loaded DC Vaccine Combined with Conventional Third-line Therapy for the Treatment of Colorectal Cancer Progressed After Second-line Treatment","Inclusion Criteria:\n\n* Patients with histologically or cytologically confirmed CRC;\n* At least one measurable lesion;\n* Aged 18-70, regardless of gender;\n* Disease progression after standard second-line therapy, and more than 2 weeks since the end of the last antitumor treatment;\n* Expected survival of ≥3 months;\n* ECOG performance status of 0-1;\n* Female patients of childbearing age must have a negative pregnancy test and be able to take effective contraceptive measures with no plans for pregnancy within six months of the study;\n* Able to undergo all screening period laboratory tests as required by the protocol;\n* Normal major organ function, such as heart, liver, and kidney;\n* Hematologic parameters: neutrophil count ≥1.5×10\\^9\u002FL, hemoglobin ≥10g\u002FdL, platelet count ≥100×10\\^9\u002FL, total bilirubin ≤1.5 times the upper limit of normal, AST and ALT ≤2.5 times the upper limit of normal, creatinine and blood urea nitrogen ≤1.5 times the upper limit of normal, activated partial thromboplastin time ≤1.5×ULN, and International Normalized Ratio or prothrombin time ≤1.5×ULN;\n* No active hepatitis, AIDS, syphilis, or other infectious diseases;\n* Rheumatoid panel: C-reactive protein (CRP) ≤10.0mg\u002FL; Anti-streptolysin O (ASO) \\\u003C500U; Erythrocyte sedimentation rate ≤15mm\u002Fh (men) or 20mm\u002Fh (women);\n* Thyroid function tests: 0.27mIU\u002FL ≤ Thyroid-stimulating hormone (TSH) ≤ 4.2mIU\u002FL; 3.1pmol\u002FL ≤ Free triiodothyronine (FT3) ≤ 6.8pmol\u002FL; 12pmol\u002FL ≤ Serum free thyroxine (FT4) ≤ 22pmol\u002FL; 1.3nmol\u002FL ≤ Serum total triiodothyronine (TT3) ≤ 3.1nmol\u002FL; 66nmol\u002FL ≤ Serum total thyroxine (TT4) ≤ 181nmol\u002FL;\n* Adrenocorticotropic hormone (ACTH): 1.1-17.6pmol\u002FL;\n* Ability to understand and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\nDisease-specific exclusion criteria:\n\n* Patients with uncontrollable brain metastases;\n* Subjects expected to require any form of antitumor treatment during the study, including maintenance therapy with other drugs, chemotherapy, and\u002For surgical resection.\n\nExclusion criteria for medical history and comorbidities:\n\n* Subjects who have required systemic treatment with corticosteroids (\\>10 mg\u002Fday of prednisone or equivalent) or other immunosuppressants within 14 days before the first dose. Inhalational or topical corticosteroids are allowed in the absence of active autoimmune diseases;\n* Subjects who have been treated with anticancer immunotherapies or other immunostimulatory anticancer drugs (interferons, interleukins, thymosin, immune cell therapy, etc.) within 3 months before the first dose;\n* Subjects participating in other clinical trials or whose first dose is less than 4 weeks (or 5 half-lives of the study drug) after the end of the previous clinical trial (last dose);\n* Subjects with severe cardiovascular diseases, such as those meeting NYHA Class II or higher criteria, myocardial infarction, or cerebrovascular accidents (cerebral ischemia, symptomatic cerebral embolism, etc.) occurring within 3 months before the first dose, or unstable arrhythmias or unstable angina within 1 month before starting study treatment;\n* Subjects with uncontrolled myocardial ischemia or myocardial infarction, poorly controlled arrhythmias are excluded;\n* Subjects with hypertension that cannot be well controlled by antihypertensive medication (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg) (Note: a stable antihypertensive regimen should be in place within 1 week before the first dose);\n* Subjects who have had significant clinically relevant bleeding symptoms or a clear bleeding tendency within 3 months before the first dose, as well as tumors that have invaded major blood vessels or, in the investigator's judgment, are highly likely to invade major blood vessels and cause major bleeding during treatment. Subjects with obvious hemoptysis, coughing up 2.5 mL or more of blood in the month before the first dose;\n* Subjects who have experienced arterial\u002Fvenous thrombotic events, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral embolism), deep vein thrombosis, and pulmonary embolism, within 3 months before screening;\n* Subjects with active tuberculosis;\n* Subjects who have had a serious infection within 4 weeks before the first dose, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.; Subjects with any active infection;\n* Subjects preparing for or who have previously undergone tissue\u002Forgan transplantation;\n* Subjects with uncontrolled epilepsy, central nervous system disorders, or neurological diseases resulting in cognitive impairment;\n* Subjects with a history of splenectomy.\n\nOther exclusion criteria:\n\n* Pregnant or breastfeeding women;\n* Subjects with a severe history of allergies or atopic constitution;\n* Subjects with a history of chronic alcohol or drug abuse within 6 months before enrollment;\n* Subjects deemed unsuitable for the study by the investigator.",{"count":136,"type":20},[86],"In this study, the investigators provide a combined treatment of personalized tumor neoantigen-loaded DC vaccine and conventional third-line therapy to patients with colorectal cancer (CRC) progressed after second-line treatment. The investigators observe the objective response rate (ORR), disease control rate (DCR), adverse event (AE), serious adverse event (SAE), progression-free survival (PFS), and overall survival (OS) , aiming to evaluate the effectiveness and safety of the treatment.",[140],[142,143,140,144,167],"Third-line Therapy",{"date":148,"type":35},{"date":150,"type":35},{"date":152,"type":20},{"name":41,"class":42},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":82,"enrollmentInfo":178,"targetDuration":4,"studyType":53,"phases":179,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":186,"leadSponsor":187,"locationsCount":154},"100573875","neoantigen-based-peptide-vaccine-and-conventional-third-line-therapy-for-crc-progressed-after-second-line-treatment-100573875","NCT06751966","Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment","A Multicenter Clinical Study of Personalized Tumor Neoantigen-based Peptide Vaccine Combined with Conventional Third-line Therapy for the Treatment of Colorectal Cancer Progressed After Second-line Treatment",{"count":136,"type":20},[86],"In this study, the investigators provide a combined treatment of personalized tumor neoantigen-based peptide vaccine and conventional third-line therapy to patients with colorectal cancer (CRC) progressed after second-line treatment. The investigators observe the objective response rate (ORR), disease control rate (DCR), adverse event (AE), serious adverse event (SAE), progression-free survival (PFS), and overall survival (OS) , aiming to evaluate the effectiveness and safety of the treatment.",[140],[142,183,140,144,167],"Peptide Vaccine",{"date":148,"type":35},{"date":150,"type":35},{"date":152,"type":20},{"name":41,"class":42},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":82,"enrollmentInfo":195,"targetDuration":4,"studyType":53,"phases":196,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":154},"100573866","phase-2-neoantigen-loaded-dc-vaccine-pd-1-inhibitor-and-radiotherapy-for-advanced-nsclc-progressed-after-second-line-treatment-100573866","NCT06751849","Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment","Personalized Tumor Neoantigen-loaded DC Vaccine Combined with PD-1 Inhibitor and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment","Inclusion Criteria:\n\n* Patients with histologically or cytologically confirmed advanced NSCLC who require radiotherapy for metastatic lesions;\n* At least one measurable lesion;\n* Aged 18-70, regardless of gender;\n* Disease progression after standard second-line therapy, and more than 2 weeks since the end of the last antitumor treatment;\n* Expected survival of ≥3 months;\n* ECOG performance status of 0-1;\n* Female patients of childbearing age must have a negative pregnancy test and be able to take effective contraceptive measures with no plans for pregnancy within six months of the study;\n* Able to undergo all screening period laboratory tests as required by the protocol;\n* Normal major organ function, such as heart, liver, and kidney;\n* Hematologic parameters: neutrophil count ≥1.5×10\\^9\u002FL, hemoglobin ≥10g\u002FdL, platelet count ≥100×10\\^9\u002FL, total bilirubin ≤1.5 times the upper limit of normal, AST and ALT ≤2.5 times the upper limit of normal, creatinine and blood urea nitrogen ≤1.5 times the upper limit of normal, activated partial thromboplastin time ≤1.5×ULN, and International Normalized Ratio or prothrombin time ≤1.5×ULN;\n* No active hepatitis, AIDS, syphilis, or other infectious diseases;\n* Rheumatoid panel: C-reactive protein (CRP) ≤10.0mg\u002FL; Anti-streptolysin O (ASO) \\\u003C500U; Erythrocyte sedimentation rate ≤15mm\u002Fh (men) or 20mm\u002Fh (women);\n* Thyroid function tests: 0.27mIU\u002FL ≤ Thyroid-stimulating hormone (TSH) ≤ 4.2mIU\u002FL; 3.1pmol\u002FL ≤ Free triiodothyronine (FT3) ≤ 6.8pmol\u002FL; 12pmol\u002FL ≤ Serum free thyroxine (FT4) ≤ 22pmol\u002FL; 1.3nmol\u002FL ≤ Serum total triiodothyronine (TT3) ≤ 3.1nmol\u002FL; 66nmol\u002FL ≤ Serum total thyroxine (TT4) ≤ 181nmol\u002FL;\n* Adrenocorticotropic hormone (ACTH): 1.1-17.6pmol\u002FL;\n* Ability to understand and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\nDisease-specific exclusion criteria:\n\n* Patients with uncontrollable brain metastases;\n* Subjects expected to require any form of antitumor treatment during the study, including maintenance therapy with other drugs, chemotherapy, and\u002For surgical resection.\n\nExclusion criteria for medical history and comorbidities:\n\n* Subjects who have required systemic treatment with corticosteroids (\\>10 mg\u002Fday of prednisone or equivalent) or other immunosuppressants within 14 days before the first dose. Inhalational or topical corticosteroids are allowed in the absence of active autoimmune diseases;\n* Subjects who have been treated with anticancer immunotherapies or other immunostimulatory anticancer drugs (interferons, interleukins, thymosin, immune cell therapy, etc.) within 3 months before the first dose;\n* Subjects participating in other clinical trials or whose first dose is less than 4 weeks (or 5 half-lives of the study drug) after the end of the previous clinical trial (last dose);\n* Subjects with severe cardiovascular diseases, such as those meeting NYHA Class II or higher criteria, myocardial infarction, or cerebrovascular accidents (cerebral ischemia, symptomatic cerebral embolism, etc.) occurring within 3 months before the first dose, or unstable arrhythmias or unstable angina within 1 month before starting study treatment;\n* Subjects with uncontrolled myocardial ischemia or myocardial infarction, poorly controlled arrhythmias are excluded;\n* Subjects with hypertension that cannot be well controlled by antihypertensive medication (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg) (Note: a stable antihypertensive regimen should be in place within 1 week before the first dose);\n* Subjects who have had significant clinically relevant bleeding symptoms or a clear bleeding tendency within 3 months before the first dose, as well as tumors that have invaded major blood vessels or, in the investigator's judgment, are highly likely to invade major blood vessels and cause major bleeding during treatment. Subjects with obvious hemoptysis, coughing up 2.5 mL or more of blood in the month before the first dose;\n* Subjects who have experienced arterial\u002Fvenous thrombotic events, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral embolism), deep vein thrombosis, and pulmonary embolism, within 3 months before screening;\n* Subjects with active tuberculosis;\n* Subjects who have had a serious infection within 4 weeks before the first dose, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.; Subjects with any active infection;\n* Subjects preparing for or who have previously undergone tissue\u002Forgan transplantation;\n* Subjects with uncontrolled epilepsy, central nervous system disorders, or neurological diseases resulting in cognitive impairment;\n* Subjects with a history of splenectomy.\n\nOther exclusion criteria:\n\n* Pregnant or breastfeeding women;\n* Subjects with a severe history of allergies or atopic constitution;\n* Subjects with a history of chronic alcohol or drug abuse within 6 months before enrollment;\n* Subjects deemed unsuitable for the study by the investigator.",{"count":136,"type":20},[197],"PHASE2","In this study, the investigators provide a combined treatment of personalized tumor neoantigen-loaded dendritic cell (DC) vaccine, PD-1 Inhibitor, and radiotherapy to patients with advanced non-small cell lung cancer (NSCLC) progressed after second-line treatment. The investigators observe the objective response rate (ORR), disease control rate (DCR), adverse event (AE), serious adverse event (SAE), progression-free survival (PFS), and overall survival (OS) , aiming to evaluate the effectiveness and safety of the treatment.",[200],"Advanced NSCLC",[142,143,202,144,203,204],"NSCLC","PD-1 Inhibitor","Radiotherapy",{"date":148,"type":35},{"date":207,"type":35},"2024-03-11",{"date":209,"type":20},"2026-06-10",{"name":41,"class":42},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":82,"enrollmentInfo":217,"targetDuration":4,"studyType":53,"phases":218,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":224,"leadSponsor":225,"locationsCount":154},"100573871","neoantigen-based-peptide-vaccine-and-conventional-second-line-therapy-for-crc-progressed-after-first-line-treatment-100573871","NCT06751914","Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment","A Multicenter Clinical Study of Personalized Tumor Neoantigen-based Peptide Vaccine Combined with Conventional Second-line Therapy for the Treatment of Colorectal Cancer Progressed After First-line Treatment",{"count":136,"type":20},[86],"In this study, the investigators provide a combined treatment of personalized tumor neoantigen-based peptide vaccine and conventional second-line therapy to patients with colorectal cancer (CRC) progressed after first-line treatment. The investigators observe the objective response rate (ORR), disease control rate (DCR), adverse event (AE), serious adverse event (SAE), progression-free survival (PFS), and overall survival (OS) , aiming to evaluate the effectiveness and safety of the treatment.",[140],[142,183,140,144,145],{"date":148,"type":35},{"date":150,"type":35},{"date":152,"type":20},{"name":41,"class":42},{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":82,"enrollmentInfo":232,"targetDuration":4,"studyType":53,"phases":233,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":239,"leadSponsor":240,"locationsCount":154},"100573870","phase-2-neoantigen-based-peptide-vaccine-pd-1-inhibitor-and-radiotherapy-for-advanced-nsclc-progressed-after-second-line-treatment-100573870","NCT06751901","Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment","Personalized Tumor Neoantigen-based Peptide Vaccine Combined with PD-1 Inhibitor and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment",{"count":136,"type":20},[197],"In this study, the investigators provide a combined treatment of personalized tumor neoantigen-based peptide vaccine, PD-1 Inhibitor, and radiotherapy to patients with advanced non-small cell lung cancer (NSCLC) progressed after second-line treatment. The investigators observe the objective response rate (ORR), disease control rate (DCR), adverse event (AE), serious adverse event (SAE), progression-free survival (PFS), and overall survival (OS) , aiming to evaluate the effectiveness and safety of the treatment.",[200],[142,183,202,144,203,204],{"date":148,"type":35},{"date":207,"type":35},{"date":209,"type":20},{"name":41,"class":42},{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":82,"enrollmentInfo":248,"targetDuration":4,"studyType":53,"phases":249,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":255,"leadSponsor":256,"locationsCount":154},"100573882","neoantigen-loaded-dc-vaccine-pd-1-inhibitor-and-radiotherapy-for-advanced-nsclc-progressed-after-first-line-treatment-100573882","NCT06752057","Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment","A Multicenter Clinical Study of Personalized Tumor Neoantigen-loaded DC Vaccine Combined with PD-1 Inhibitor and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment","Inclusion Criteria:\n\n* Patients with histologically or cytologically confirmed advanced NSCLC who require radiotherapy for metastatic lesions;\n* At least one measurable lesion;\n* Aged 18-70, regardless of gender;\n* Disease progression after standard first-line therapy, and more than 2 weeks since the end of the last antitumor treatment;\n* Expected survival of ≥3 months;\n* ECOG performance status of 0-1;\n* Female patients of childbearing age must have a negative pregnancy test and be able to take effective contraceptive measures with no plans for pregnancy within six months of the study;\n* Able to undergo all screening period laboratory tests as required by the protocol;\n* Normal major organ function, such as heart, liver, and kidney;\n* Hematologic parameters: neutrophil count ≥1.5×10\\^9\u002FL, hemoglobin ≥10g\u002FdL, platelet count ≥100×10\\^9\u002FL, total bilirubin ≤1.5 times the upper limit of normal, AST and ALT ≤2.5 times the upper limit of normal, creatinine and blood urea nitrogen ≤1.5 times the upper limit of normal, activated partial thromboplastin time ≤1.5×ULN, and International Normalized Ratio or prothrombin time ≤1.5×ULN;\n* No active hepatitis, AIDS, syphilis, or other infectious diseases;\n* Rheumatoid panel: C-reactive protein (CRP) ≤10.0mg\u002FL; Anti-streptolysin O (ASO) \\\u003C500U; Erythrocyte sedimentation rate ≤15mm\u002Fh (men) or 20mm\u002Fh (women);\n* Thyroid function tests: 0.27mIU\u002FL ≤ Thyroid-stimulating hormone (TSH) ≤ 4.2mIU\u002FL; 3.1pmol\u002FL ≤ Free triiodothyronine (FT3) ≤ 6.8pmol\u002FL; 12pmol\u002FL ≤ Serum free thyroxine (FT4) ≤ 22pmol\u002FL; 1.3nmol\u002FL ≤ Serum total triiodothyronine (TT3) ≤ 3.1nmol\u002FL; 66nmol\u002FL ≤ Serum total thyroxine (TT4) ≤ 181nmol\u002FL;\n* Adrenocorticotropic hormone (ACTH): 1.1-17.6pmol\u002FL;\n* Ability to understand and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\nDisease-specific exclusion criteria:\n\n* Patients with uncontrollable brain metastases;\n* Subjects expected to require any form of antitumor treatment during the study, including maintenance therapy with other drugs, chemotherapy, and\u002For surgical resection.\n\nExclusion criteria for medical history and comorbidities:\n\n* Subjects who have required systemic treatment with corticosteroids (\\>10 mg\u002Fday of prednisone or equivalent) or other immunosuppressants within 14 days before the first dose. Inhalational or topical corticosteroids are allowed in the absence of active autoimmune diseases;\n* Subjects who have been treated with anticancer immunotherapies or other immunostimulatory anticancer drugs (interferons, interleukins, thymosin, immune cell therapy, etc.) within 3 months before the first dose;\n* Subjects participating in other clinical trials or whose first dose is less than 4 weeks (or 5 half-lives of the study drug) after the end of the previous clinical trial (last dose);\n* Subjects with severe cardiovascular diseases, such as those meeting NYHA Class II or higher criteria, myocardial infarction, or cerebrovascular accidents (cerebral ischemia, symptomatic cerebral embolism, etc.) occurring within 3 months before the first dose, or unstable arrhythmias or unstable angina within 1 month before starting study treatment;\n* Subjects with uncontrolled myocardial ischemia or myocardial infarction, poorly controlled arrhythmias are excluded;\n* Subjects with hypertension that cannot be well controlled by antihypertensive medication (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg) (Note: a stable antihypertensive regimen should be in place within 1 week before the first dose);\n* Subjects who have had significant clinically relevant bleeding symptoms or a clear bleeding tendency within 3 months before the first dose, as well as tumors that have invaded major blood vessels or, in the investigator's judgment, are highly likely to invade major blood vessels and cause major bleeding during treatment. Subjects with obvious hemoptysis, coughing up 2.5 mL or more of blood in the month before the first dose;\n* Subjects who have experienced arterial\u002Fvenous thrombotic events, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral embolism), deep vein thrombosis, and pulmonary embolism, within 3 months before screening;\n* Subjects with active tuberculosis;\n* Subjects who have had a serious infection within 4 weeks before the first dose, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.; Subjects with any active infection;\n* Subjects preparing for or who have previously undergone tissue\u002Forgan transplantation;\n* Subjects with uncontrolled epilepsy, central nervous system disorders, or neurological diseases resulting in cognitive impairment;\n* Subjects with a history of splenectomy.\n\nOther exclusion criteria:\n\n* Pregnant or breastfeeding women;\n* Subjects with a severe history of allergies or atopic constitution;\n* Subjects with a history of chronic alcohol or drug abuse within 6 months before enrollment;\n* Subjects deemed unsuitable for the study by the investigator.",{"count":136,"type":20},[86],"In this study, the investigators provide a combined treatment of personalized tumor neoantigen-loaded dendritic cell (DC) vaccine, PD-1 Inhibitor, and radiotherapy to patients with advanced non-small cell lung cancer (NSCLC) progressed after first-line treatment. The investigators observe the objective response rate (ORR), disease control rate (DCR), adverse event (AE), serious adverse event (SAE), progression-free survival (PFS), and overall survival (OS) , aiming to evaluate the effectiveness and safety of the treatment.",[200],[142,143,202,144,203,204],{"date":148,"type":35},{"date":150,"type":35},{"date":152,"type":20},{"name":41,"class":42},{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":82,"enrollmentInfo":263,"targetDuration":4,"studyType":53,"phases":264,"briefSummary":265,"conditions":266,"keywords":267,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":270,"leadSponsor":271,"locationsCount":154},"100573881","neoantigen-based-peptide-vaccine-pd-1-inhibitor-and-radiotherapy-for-advanced-nsclc-progressed-after-first-line-treatment-100573881","NCT06752044","Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment","A Multicenter Clinical Study of Personalized Tumor Neoantigen-based Peptide Vaccine Combined with PD-1 Inhibitor and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment",{"count":136,"type":20},[86],"In this study, the investigators provide a combined treatment of personalized tumor neoantigen-based peptide vaccine, PD-1 Inhibitor, and radiotherapy to patients with advanced non-small cell lung cancer (NSCLC) progressed after first-line treatment. The investigators observe the objective response rate (ORR), disease control rate (DCR), adverse event (AE), serious adverse event (SAE), progression-free survival (PFS), and overall survival (OS) , aiming to evaluate the effectiveness and safety of the treatment.",[200],[142,183,202,144,203,204],{"date":148,"type":35},{"date":150,"type":35},{"date":152,"type":20},{"name":41,"class":42},{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":278,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":279,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":74},"100533793","exploring-the-mechanism-of-severe-acute-pancreatitis-based-on-metagenomics-metabolomics-and-proteomics-100533793","NCT06230432","Exploring the Mechanism of Severe Acute Pancreatitis Based on Metagenomics, Metabolomics and Proteomics","Inclusion Criteria:\n\nPatients group:\n\n① Age between 18 and 75 years old;\n\n② Within 72 hours of AP onset;\n\n③ AP patients who meet the 2012 Atlanta AP Classification and Diagnostic Criteria.\n\nHealthy control group:\n\n* Age between 18 and 75 years old; ② No history of acute pancreatitis; ③ Routine laboratory tests such as blood routine and fecal routine are normal.\n\nExclusion Criteria:\n\n* Used antibiotics, probiotics, and acid suppressants 4 weeks before enrollment;\n\n  * Pregnant and lactating women;\n\n    * Hypothyroidism, nephrotic syndrome, Cushing's syndrome, AIDS;\n\n      * Chronic pancreatitis, pancreatic cancer; ⑤ Severe history of cardiovascular and cerebrovascular diseases and organ dysfunction, such as malignant tumors, heart failure, coronary heart disease, chronic obstructive pulmonary disease, liver and kidney failure; ⑥ Unsigned informed consent form.",true,{"count":280,"type":20},176,"The goal of this observational study is to learn about the biomarkers and mechanisms of severe acute pancreatitis in 30 healthy controls, 30 patients of mild acute pancreatitis, 30 patients of moderately severe acute pancreatitis, and 86 patients of severe acute pancreatitis. The main question it aims to answer are: • The relationship between changes in gut microbiota and clinical prognosis (plasma inflammatory cytokines, incidence and duration of infection in various parts, mortality rate), and the screening and validation of biomarkers that can be used for early prediction of disease severity. • Analyze the relationship between changes in blood composition and clinical prognosis (plasma inflammatory cytokines, incidence and duration of infection in various parts, mortality rate), screen and verify biomarkers that can be used for early prediction of disease severity. Blood and fecal samples from the healthy control group and diagnosed patients will be collected.",[116],"2024-01-20",{"date":285,"type":35},"2024-01-30",{"date":287,"type":20},"2024-01-21",{"date":289,"type":20},"2026-12-09",{"name":41,"class":42},{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":53,"phases":300,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":74},"100525209","phase-4-clinical-study-of-fruquintinib-combined-with-raltitrexed-in-the-treatment-of-metastatic-colorectal-cancer-100525209","NCT06118762","Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer","A Single-arm, Open, Multicenter Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer","Inclusion Criteria:\n\n1. Have fully understood the study and voluntarily signed the informed consent;\n2. Age ≥18 years old, gender unlimited;\n3. Advanced metastatic colorectal adenocarcinoma confirmed by histopathology;\n4. The patient progressed or was intolerant after receiving at least previous standard therapy containing fluorouracil, oxaliplatin, and irinotecan.\n\n   * Each first-line treatment must include one or more chemotherapeutic agents for a duration of ≥1 cycle;\n   * Allow pre-adjuvant\u002Fneoadjuvant therapy. If recurrence or metastasis occurs during or within 6 months after completion of adjuvant\u002Fneoadjuvant therapy, adjuvant\u002Fneoadjuvant therapy is considered a failure of first-line chemotherapy for advanced disease;\n   * Prior chemotherapy combined with cetuximab or bevacizumab is permitted;\n5. Have at least one measurable lesion (RECIST 1.1 standard);\n6. Eastern Cooperative Oncology Group (ECOG) physical condition 0-1 score;\n7. Expected survival ≥12 weeks;\n8. The functions of vital organs during the first 14 days of enrollment meet the following requirements (the use of any blood components and cell growth factors during the first 14 days of enrollment is not allowed) :\n\n   * Absolute neutrophil count ≥1.5×109\u002FL;\n   * Platelet ≥80×109\u002FL;\n   * Hemoglobin ≥8g\u002FdL;\n   * Total bilirubin \\\u003C 1.5 × upper limit of normal（ULN）;\n   * Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) \\\u003C 2.5 × ULN (\\\u003C 5 × ULN in patients with liver metastasis);\n   * Serum creatinine ≤1 × ULN;\n   * endogenous creatinine clearance \\> 50ml\u002Fmin;\n9. Women of childbearing age or men whose partners wish to have children need to take effective contraceptive measures.\n\nExclusion Criteria:\n\n1. Previous treatment with Fruquintinib or other anti-vascular endothelial growth factor receptor (VEGFR) inhibitors such as Apatinib, Regorafenib, and Anlotinib;\n2. Previous treatment with Raltitrexed;\n3. Participated in other drug clinical trials and received at least one drug therapy within four weeks prior to enrollment or received other systemic anti-tumor therapy, including chemotherapy, signal transduction inhibitors, hormone therapy, and immunotherapy within four weeks prior to enrollment;\n4. The patient currently has a disease or condition that affects drug absorption, or the patient cannot take Fruquintinib orally;\n5. The patient currently has gastrointestinal diseases such as gastric and duodenal active ulcers, ulcerative colitis, or active bleeding from unresectable tumors, or other conditions determined by researchers that may cause gastrointestinal bleeding or perforation;\n6. Patients with active bleeding or bleeding tendency;\n7. History of severe cardiovascular and cerebrovascular diseases:\n\n   * Cerebrovascular accident (excluding lacunar infarction, minor cerebral ischemia, or transient ischemic attack), myocardial infarction, unstable angina, and poorly controlled arrhythmias (including QTc interval ≥ 450ms for men and 470 ms for women) within 6 months prior to first administration of the study drug (QTc interval Fridericia) Formula calculation);\n   * New York Heart Association (NYHA) Heart Function Rating \\> Grade II or left ventricular ejection fraction (LVEF) \\\u003C 50%;\n8. Have had other malignancies within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;\n9. Clinically uncontrolled active infections, such as acute pneumonia, active hepatitis B or C (hepatitis B virus infection regardless of drug control, hepatitis B virus DNA≥1×104 copies \u002FmL or \\> 2000 IU\u002Fml);\n10. There is known to be symptomatic central nervous system metastasis and\u002For cancerous meningitis. Participants with previously treated brain metastases may participate in the trial if their condition is stable (no evidence of radiographic progression at least 4 weeks prior to initial administration of the trial treatment), repeated radiographic studies confirm no evidence of new brain metastases or enlargement of the original brain metastases, and no steroid therapy is required at least 14 days prior to initial administration of the trial treatment. This exception does not include cancerous meningitis, which should be excluded regardless of whether it is clinically stable;\n11. Women who are pregnant (positive pregnancy test before medication) or breastfeeding;\n12. The patient currently has hypertension that cannot be controlled by drugs, which is prescribed as: systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg after taking antihypertensive drugs;\n13. Urine routine indicates urinary protein ≥2+, or 24-hour urinary protein volume \\> 1.0g;\n14. The patients considered by the investigators to be unsuitable for inclusion in this study.",{"count":299,"type":20},30,[301],"PHASE4","To evaluate the efficacy and safety of Fruquintinib combined with Raltitrexed in the treatment of metastatic colorectal cancer that progressed or could not be tolerated after previous fluorouracil, oxaliplatin, and irinotecan based therapy",[304],"Metastatic Colorectal Cancer",[306,307,308],"metastatic colorectal cancer","Fruquintinib","Raltitrexed","2023-11-01",{"date":311,"type":35},"2023-11-07",{"date":313,"type":35},"2023-10-20",{"date":315,"type":20},"2026-10-01",{"name":41,"class":42},""]